Scientific Program

Scientific Program

SUNDAY – July 9
KEY TO TRACK THEMES
8:00-12:00Pre-Congress SymposiaSTI guidelines and STI estimates – WHO Overview of the WHO guideline development process Treatment guidelines for Neisseria gonorrhoea Treatment guidelines for Chlamydia trachomatis Treatment guidelines for Treponema pallidum Treatment guidelines for genital herpes simplex infection Syphilis screening and treatment for syphilis among pregnant women Road map for the development of new treatment for Neisseria gonorrhoea Overview of the STI surveillance STI Spectrum : National STI estimation tool Congenital syphilis estimation toolProgram Science Welcome and Introduction
Interventional polygamy in the real world: the challenges of assessing impact Intervention Impact in the Real World and the Randomized World Mathematical modeling to support STD program design and evaluation Geographic Correlates of Primary and Secondary Syphilis in MSM: A New Focus for Intervention? A Canadian Knowledge Exchange Forum on Syphilis: Lessons Learned from Rural and Urban Perspectives Maximizing Impact of New HIV Prevention Technologies in Sub-Saharan Africa Evaluating the implementation of combination prevention programs through individually assessed indicators of exposure to community and clinical interventions, and introduction of treatment as prevention and pre-exposure prophylaxis among female sex workers in Cotonou, Benin Improving Male Circumcision Coverage in South Africa: Using a Prevention Cascade to Ensure a Comprehensive Integrated Approach Operationalising Program Science in Mombasa, Kenya: Key lessons from an HIV prevention Learning Site for Sex Workers Early HIV risk and gaps in programme access: an observational and mathematical modeling study of young female sex workers in Kenya and Ukraine
How to read a Cochrane Systematic Review of interventions Dr. Hernando Guillermo Gaitan Duarte, National University of Colombia Basic concepts of systematic reviews Defining the clinical questions PICO Question Format Where to find systematic reviews How to assess quality of SR How to use a Cochrane SR How to read GRADE evidence profilesHIV Research perspectives in Latin American women The STI and HIV epidemic in women and girls in Latin America: overview of the current situation NIH priorities for HIV research and funding Providing a woman-centered, life-course approach to addressing women’s vulnerability to STI and HIV: the example of the WHO Guidelines on SRHR of Women Living with HIV Development and implementation of tools to strengthen gender-sensitive national STI, HIV and SRH monitoring and evaluation systems Challenges in addressing research gaps and priorities to advance the health agenda for women and girls in Latin America Health-care policy and provision in cases of sexual violence against women Research linking biomedical and structural interventions to reach adolescent girls and young women in Latin America with HIV and STI prevention Discussion – Vulnerable populations at risk or living with STI and HIV: Indians, quilombo (isolated African descendants), young people, commercial sex workers and transgender personsSYSTEMS BIOLOGY
CLINICAL SCIENCE
1:00-5:00Partner Round table on STI strategy – WHO Ending epidemics: building on global momentum towards country impact Addressing Resource Needs: Opportunities for Partner CollaborationEPIDEMIOLOGY
BEHAVIOR/SOCIAL SCIENCE
5:30 – 6:00WELCOME CEREMONYBIOMEDICAL STI/HIV PREVENTION
POLICY
6:15-7:00KEYNOTE LECTURE: HIV, STIs and Evolution in Global Health – Dr. Kevin M. De Cock, Director, US Centers for Disease Control and Prevention, Kenya
MULTIDISCIPLINARY
07:30WELCOME RECEPTIONLATE-BREAKER
MONDAY -July 10
7:00 – 8:30ASTDA Breakfast session: Connecting human and sexual rights to STI/HIV prevention
7:15-8:15Clinical case series
8:30-9:15PLENARY 1 and 2nd IUSTI Prestigious Lecture: Update on vaginal microbiome research – Dr. Jeanne Marrazzo
Director, University of Alabama at Birmingham School of Medicine, Division of Infectious Diseases, USA
9:15-9:45PLENARY 2: Implications of Implementation of PrEP – Dr. Sinead Delany-Moretlwe
Director of Research, University of Witwatersrand, Johannesburg, South Africa
9:45-10:15PLENARY 3: Maternal-to-child Syphilis Transmission/Elimination in Latin America – Dr. Suzanne Serruya – Director, Centro Latino-Americano de Perinatologia (CLAP),
Pan American Health Organization, Uruguay.
9:15-10:30Morning plenary question period
10:30-11:15COFFEE BREAK
11:15-12:30SYMPOSIUM 1: New technologies for diagnosis, characterization and control of STIs/HIVSYMPOSIUM 2: Mathematical modeling and decision making in the world of STIsSYMPOSIUM 3: Latest generation point-of-care tests for STIs/HIV – a marriage of innovation and technologyORAL PRESENTATION SESSION 1 (10 MIN TALKS)ORAL PRESENTATION SESSION 2ORAL PRESENTATION SESSION 3
Characterizing HIV mucosal transmission through identifying the early foci of viral infection 48 hours after exposure – Dr. Thomas Hope, Department of Cell and Molecular Biology, Northwestern University, Chicago, Illinois, USAUse of modelling for evaluation of HIV/STI interventions – Dr. Michel Alary, Département de médecine sociale et préventive, Faculté de médecine Université Laval, Quebec, canadaSTI broad spectrum POC or Self testing in advanced settings – Dr. Tariq Sadiq, St. George’s University of London, UKTALK 1TALK 1TALK 1
TALK 2TALK 2TALK 2
Natural history of HPV-related tumors: key to prevention and therapeutics – Dr. Luisa Villa, Department of Radiology and Oncology, School of Medicine, Universidade de São Paulo, BrazilThe role of mathematical modelling in policy – Dr. Nicola Low, Institute of Social and Preventive Medicine, University of Bern, SwitzerlandPOC testing and information technology, including HIV self testing in LMIC; how to scale up point-of-care technology – Dr. Rosanna Peeling, London School of Hygiene and Tropical Medicine, UKTALK 3TALK 3TALK 3
TALK 4TALK 4TALK 4
New technologies for diagnosis and characterization of Chlamydia trachomatis – Dr. Angelika Stary, Division of Immunology, Allergy, and Infectious Diseases, General Hospital, University of Vienna, AustriaIntegrating population genomics and mathematical modeling to control antibiotic resistance in gonococcus – Dr. Yonatan Grad, Immunology and Infectious Diseases Department, Harvard TH Chan School of Public Health, USAPoint-of-care testing and treatment of sexually transmitted and genital infections to improve birth outcomes in high-burden, low-income settings – Dr. Andrew Vallely, Public Health Interventions Research Group, the Kirby Institute for Infection and Immunity in Society, Faculty of Medicine, UNSW, AustraliaTALK 5TALK 5TALK 5
TALK 6TALK 6TALK 6
12:30-2:00LUNCH
12:30-2:00INDUSTRY SPONSORED SATELLITE SYMPOSIA
1:00-2:00IUSTI World General Assembly
2:00-3:30SYMPOSIUM 4: The digital age and sexual health: friend or foe?SYMPOSIUM 5: Progress on STI VaccinesSYMPOSIUM 6: Policy Gaps and Opportunities in the Elimination of Congenital SyphilisORAL PRESENTATION SESSION 4 (10 MIN TALKS)ORAL PRESENTATION SESSION 5ORAL PRESENTATION SESSION 6
INTRODUCTION – NIH/WHO
Integrating STI self-testing into an eHealth prevention program for young MSM: The Keep It Up! 2.0 trial. Dr. Brian Mustanski, Department of Medical Social Sciences and Institute for Sexual and Gender Minority Health and Wellbeing, Northwestern University, Chicago, ILProgress on a Gonorrhea Vaccine – Dr. Ann Jerse, Department of Microbiology and Immunology, Uniformed Services University, USAAchievements and updates in global guidance for EMTCT validation. Dr. Melanie Taylor, World Health OrganizationTALK 1TALK 1TALK 1
TALK 2TALK 2TALK 2
Engaging youth in innovative technologies across the HIV prevention and care continuum: A review of the iTech portfolio. Dr. Lisa Hightow-Weidman, Institute for Global Health and Infectious Diseases University of North Carolina, Chapel Hill NCProgress on a Syphilis Vaccine – Dr. Sheila Lukehart, Division of Infectious Diseases, University of Washington, USATowards triple elimination of mother to child transmission of HIV, syphilis and hepatitis B. Dr. Massimo Ghinidelli, Pan American Health OrganizationTALK 3TALK 3TALK 3
Asia Pacific regional framework for triple elimination of mother-to-child transmission of HIV, syphilis and hepatitis B – opportunities for synergies. Dr. Naoko Ishikawa, Western Pacific Region, World Health OrganizationTALK 4TALK 4TALK 4
The role of STI testing in a mobile prevention app focused on HIV prevention for MSM. Dr. Patrick Sullivan, Department of Epidemiology, Emory University, Atlanta GAProgress on a Herpes Simplex Virus Vaccine – Dr. Anna Wald, Department of Epidemiology, University of Washington, USAShortages of benzathine penicillin: identifying opportunities to ensure stable and adequate supply – Margaret Savage, MSc, Clinton Health Access Initiative
TALK 5TALK 5TALK 5
There’s an app for that: What role do geospatial networking apps play in STI outbreaks? Dr. Hamish Mohammed,
Department of HIV and STIs, Centre for Infectious Disease Surveillance and Control, National Infection Service, Public Health England, London UK
Progress towards a Chlamydia trachomatis STI vaccine – Dr. Peter Timms, Department of Microbiology, University of the Sunshine Coast Queensland, AustraliaRole of rapid tests in the elimination of congenital syphilis, Dr. Adele Benzaken, Director, Department of STDs, AIDS and viral hepatitis, Ministry of Health, Brazil
TALK 6TALK 6TALK 6
3:30-4:00OVERVIEW/WRAP UP – WHO/NIH
3:30 – 4:15COFFEE BREAK
4:15-4:45PLENARY 4: Refugees and HIV/STI risks and responses – Dr. Paul Spiegel
Harvard Medical School, Cambridge, Massachusetts, USA
4:45-5:15PLENARY 5: Know your status: How we can harness the power of dating apps to educate and empower around HIV/STI prevention – Mr. Alex Garner
Senior Health Innovation Strategist, Hornet gay social networking app, USA
5:15-5:30Evening plenary question period
5:30-6:00Debate: Sexual education starting at age 4: is it too early? Dr. Mark Schuster, Harvard Medical School, Boston, MA, USA. Dr. Dennis Fortenberry, Indiana University, Indianapolis, IN, USA
6:00-7:00POSTER VIEWING
7:00-8:30
TUESDAY – July 11
7:00 – 8:30WHO-NIH organized meeting with potential partners of the STI vaccine consortium
7:30-8:30Clinical Case Series
8:45:-9:15PLENARY 6: Biomarkers for HIV Risk using Systems Biology Tools – Dr. Douglas Kwon, Harvard Medical School, Cambridge, Massachusetts, USA
9:15-9:45PLENARY 7: Zika virus: Vectorial vs. sexual transmission, what we know and why it matters – Dr. Flavio Codeco Coelho, Professor, School of Applied Mathematics at Fundação Getulio Vagas, Head of the Mathematical Epidemiology Center, Rio de Janeiro, Brazil
9:45-10:15PLENARY 8: Surveillance of neglected STIs, the evolving landscape – Dr. Gwenda Hughes, Head of STI Surveillance Section at the national Centre for Infectious Disease Surveillance and Control at Public Health, UK
10:15-10:30Morning plenary question period
10:30-11:15COFFEE BREAK
11:15-12:30SYMPOSIUM 7: Noncondom-based interventions for STI controlSYMPOSIUM 8: The Dual Epidemics of STIs and HIV in WomenSYMPOSIUM 9: Evolution and global spread of resistance in STIsORAL PRESENTATION SESSION 7 (10 MIN TALKS)ORAL PRESENTATION SESSION 8ORAL PRESENTATION SESSION 9
Does doxycycline prophylaxis have a future? – Dr. Jeffrey Klausner, Department of Epidemiology, UCLA, USAEvolution and global spread of resistance in Neisseria gonorrhoeae – Dr. Magnus Unemo, Department of Laboratory Medicine, Microbiology, Örebro University Hospital, SwedenTALK 1TALK 1TALK 1
TALK 2TALK 2TALK 2
Vaccination threshold for epidemics – Dr. David Regan, The University of New South Wales, AustraliaInvestigating combination HIV prevention: isolated interventions or a complex system? Dr. Gina Brown, National Institutes of Health, Bethesda, Maryland, USAEvolution and global spread of resistance in Mycoplasma genitalium – Dr. Catriona Bradshaw, Central Clinical School, Monash University, AustraliaTALK 3TALK 3TALK 3
TALK 4TALK 4TALK 4
Risk Compensation in Men who have Sex with Men in the era of Biomedical (non-condom) Interventions – Dr. Henry de Vries, University of Amsterdam, NetherlandsThe role of the vaginal microbiome in STI/HIV prevention. Dr. Jen Balkus, Department of Global Health, University of Washington, Seattle, WA, USAAre we treating chlamydia adequately? – Dr. Basil Donovan, Head of the Sexual Health Program at the Kirby Institute, UNSW AustraliaTALK 5TALK 5TALK 5
Sexual and reproductive health and rights of young women at risk of HIV/STIs. Dr. Manjulaa Narasimhan, World Health OrganizationTALK 6TALK 6TALK 6
12:30-2:00LUNCH
12:30-2:00ASTDA AWARD LUNCHEON
12:30-2:00INDUSTRY SPONSORED SATELLITE SYMPOSIA
12:30-2:00POSTER VIEWING
2:00-3:30SYMPOSIUM 10: Tackling antimicrobial resistance in Neisseria gonorrhoeae: a need for a comprehensive and collaborative approachSYMPOSIUM 11: Monitoring of M. genitalium amongst the clinical, microbiology and public health communities: who should (and should not) be tested?SYMPOSIUM 12: STIs IN MSM; WHAT WILL BE NEW IN THE FUTURE?ORAL PRESENTATION SESSION 10 (10 MIN TALKS)ORAL PRESENTATION SESSION 11ORAL PRESENTATION SESSION 12
Linking control and impact of AMR in N. gonorrhoeae to the global antimicrobial action plan. Dr. Pilar Ramon-Pardo. Pan American Health Organization.Microbiology and Infection Control, Statens Serum Institut, Copenhagen, Denmark – Dr. Jørgen Skov Jensen, Microbiology and Infection Control, Statens Serum Institut, Copenhagen, DenmarkUnderstanding transmission dynamics – allows new interventions – Dr. Christopher K Fairley, Public Health Monash University, Director Melbourne Sexual Health Centre, AustraliaTALK 1TALK 1TALK 1
TALK 2TALK 2TALK 2
Monitoring antimicrobial resistance in N. gonorrhoeae in Latin America. Dr. Patricia Galarza, Administracion Nacional de Laboratorios, ArgentinaCurrent Status of Diagnostic Assays for Mycoplasma genitalium – Dr. Charlotte Gaydos, Division of Infectious Diseases, Department of Medicine of the Johns Hopkins University School of Medicine, USAScanning the horizon: anticipated and threatened STI outbreaks within MSM communities – Dr. David Lewis, Western Sydney Sexual Health Centre, and Marie Bashir Institute for Infectious Diseases and Biosecurity, Sydney Medical School – Westmead, University of Sydney, AustraliaTALK 3TALK 3TALK 3
Reducing N. gonorrhoeae infection: Appropriate treatment and new drugs in the pipeline and gonorrhoea vaccines. Dr. Carolyn Deal, National Institutes of Health, Washington, DC, USAClinical management of M. genitalium. Dr. Lisa Manhart, University of Washington, Seattle, WA, USASexual identities and HIV/STI prevention among MSM – Dr. Carlos Caceres, Universidad Peruana Cayetano Heredia, Lima, PeruTALK 4TALK 4TALK 4
TALK 5TALK 5TALK 5
Identifying new technologies and approaches for detecting AMR in low and middle income countries. Dr. Jo-Anne Dillon, Department of Microbiology and Immunology, University of Saskatchewan, Saskatoon, SK, CanadaBe-PrEP-ared study: a cohort of 200 high risk MSM in BelgiumChemsex, sexual behavior and HIV/STI prevention among MSM – Dr. Mark Pakianathan, St. George’s University Hosptials, London, EnglandTALK 6TALK 6TALK 6
3:30-4:00COFFEE BREAK
4:00-4:30PLENARY 9: A new focus for social and behavioral research in the era of biomedical advances in STI and HIV treatment and prevention – Dr. Patricia Dittus
Division of STD Prevention, Centers for Disease Control and Prevention, USA
4:30-5:00PLENARY 10: TBD
5:00-5:20Evening plenary question period
5:20-5:50debate: Global public health agencies should make PrEP available on-demand: Dr. Matt Golden, University of Washington, Seattle, WA, USA; Dr. Beatriz Grinsztejn, Oswaldo Cruz Foundation, Brazil
6:00-7:00POSTER VIEWING
07:30GALA DINNER
WEDNESDAY – July 12
7:30-8:30Clinical Case Series
8:45:-9:15PLENARY 11: Policy & Community Engagement: Challenges for PrEP – Dr. Fabio Mesquita, World Health Organization
9:15-9:45PLENARY 12: The Future of Anal Cancer Prevention – Dr. Andrew Grulich
Head, HIV Epidemiology and Prevention Program, The Kirby Institute, University of New South Wales, Australia
9:45-10:00Morning plenary question period
10:00-10:45COFFEE BREAK
10:45-12:00SYMPOSIUM 13: Probiotics for the treatment of vaginal conditions and vaginal microbiomeSYMPOSIUM 14: Policy’s Role in STD/HIV Prevention (20 MINUTE TALKS)ORAL PRESENTATION SESSION 13 (10 MIN TALKS) – CROSSOVER BIOMEDICAL/SYSTEMS BIOLOGYORAL PRESENTATION SESSION 14ORAL PRESENTATION SESSION 15ORAL PRESENTATION SESSION 16-CROSSOVER
The vaginal microbiome and STIs – Dr. Janneke van de Wijgert, Institute of Infection and Global Health, University of Liverpool, UKLGBT Policies – Sexual and Reproductive HealthTALK 1TALK 1TALK 1TALK 1
TALK 2TALK 2TALK 2TALK 2
Microbiome composition and function in the female genital tract – Dr. Craig Cohen, Department of Obstetrics, Gynecology & Reproductive Sciences
Bixby Center for Global Reproductive Health
University of California San Francisco, USA
The Sustainable Development Goals & Global Health Sector Strategies 2016-2021: Policy implications for HIV, STIs and Viral HepatitisTALK 3TALK 3TALK 3TALK 3
TALK 4TALK 4TALK 4TALK 4
Characteristics of Vaginal Microbicides in Women with Bacterial Vaginosis- Dr. Sharon Hillier, Department of Microbiology and Molecular Genetics, University of Pittsburgh, USATALK 5TALK 5TALK 5TALK 5
TALK 6TALK 6TALK 6TALK 6
12:00-1:30LUNCH
1:30-3:00SYMPOSIUM 15: Program science applied to the Latin America National program: country specific results?SYMPOSIUM 16: Pre-Exosure Prophylaxis (PrEP) of HIV: imapct on sexually transmitted infections (STIs) and lessons learned from real-life implementationRESERVED SYMPOSIUMORAL PRESENTATION SESSION 17-CROSSOVERLATE BREAKER SESSIONLATE BREAKER SESSION
Organized by CDCTALK 1TALK 1TALK 1
TALK 1New WHO implementation guidance on use of PrEP for HIV prevention. Dr. Ioannis Hodges-Mameletzis, World Health OrganizationTALK 1TALK 2TALK 2TALK 2
Panel on PrEP of HIV: impact on STIs and lessons learned from real-life implementationTALK 2TALK 3TALK 3TALK 3
TALK 2Latin America Experience. Dr. Beatriz Grinsztejn, FIOCRUZ Rio de Janeiro, BrazilTALK 3TALK 4TALK 4TALK 4
European experience. Dr. Andrew Grulich, University of New South Wales, AustraliaTALK 4TALK 5TALK 5TALK 5
TALK 3African experienceTALK 6TALK 6TALK 6
Thailand experience
TALK 4
3:00-3:30Coffee Break
3:30-4:00CLOSING CEREMONY REMARKS
4:00-4:30CLOSING CEREMONY